WuXi BioLogics wins Adagene antibody therapeutics contract

By Flora Southey

- Last updated on GMT

WuXi BioLogics will develop and manufacture Adagene’s antibody therapeutics for the Chinese market before expanding globally.

The strategic collaboration will see the Hong-Kong-headquartered contract development and manufacturing organisation (CDMO) make antigen-focused therapies.

“This collaboration is expected to introduce the world-class life-saving biologics to the Chinese market, and then benefit patients around the world,” ​said WuXi BioLogics CEO Chris Chen in a statement​.

The antibody therapeutics will be developed at WuXi BioLogics’ biologics development facility​ in Shanghai, and made at its manufacturing site​ in WuXi City, spokesperson Lia Jia told us.

WuXi BioLogics’ manufacturing plant – located 100km west of Shanghai – consists of two 1,000L single-use bioreactors, and 14 2,000L fed-batch cell culture disposable vessles supplied​ by vendor Thermo Fisher.

Three months ago the CDMO announced​ it had initiated current good manufacturing practice (cGMP) production at the site.

At the time, WuXi BioLogics told told Biopharma-Reporter the facility’s 30,000L capacity was already “mostly filled.”

Related news

Show more

Related products

show more

Related suppliers

Follow us